|
Big Ten CRC News & Events
|
|
University of Maryland Greenebaum Comprehensive Cancer Center joins Big Ten Cancer Research Consortium
Located in Baltimore, Md., UMGCCC offers innovative approaches to diagnosing and treating all types of cancer, conducts cutting-edge research to bring the latest advances in cancer treatment directly to patients in Maryland and beyond, and provides cancer screening and patient education services.
UMGCCC is one of 51 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, recognized for its excellence in patient care and multidisciplinary translational research program. More than 200 physicians and scientists work together at the cancer center, a joint entity of the University of Maryland Medical Center and the University of Maryland School of Medicine.
|
|
Gaskins, Bachanova appointed to Steering Committee
The Big Ten CRC recently welcomed two new members to its Steering Committee, which meets on a regular basis to review activities of the consortium and decide matters of policy.
Veronika Bachanova, MD, PhD, was appointed to represent the University of Minnesota, and
H. Rex Gaskins, PhD, was selected to represent the University of Illinois at Urbana-Champaign.
|
|
Big Ten CRC studies presented at SABCS, GI ASCO
Big Ten CRC investigators presented studies at the 2019 San Antonio Breast Cancer Symposium (SABCS) and the 2020 Gastrointestinal Cancers Symposium (GI ASCO).
At SABCS,
BTCRC-BRE18-337
authors, led by Sneha Phadke, DO (pictured left), and Kari Wisinski, MD (right), reported on the study during an ongoing trials session.
BTCRC-BRE15-016
authors, led by Dr. Wisinski and Oana Danciu, MD (center),
noted that study is one of the first
trials to assess the safety of the combination of palbociclib with tamoxifen in metastatic hormone receptor positive breast cancer.
At GI ASCO, Hirva Mamdani, MD (right), presented two-year follow-up results from the BTCRC-ESO14-012 study, and Nataliya Uboha, MD, PhD (left), presented an ongoing trials poster highlighting BTCRC-GI18-149.
Congratulations to all authors and study teams!
Read more:
|
|
University of Nebraska
Investigator Spotlight
Benjamin Teply, MD, is a medical oncologist engaged in clinical and translational research in genitourinary malignancies. His research interests include novel treatment strategies for prostate cancer, with a focus on mechanisms other than suppression of androgen signaling, in both treatment-naïve (such as PARP inhibition) and castration-resistant prostate cancer (such as therapeutic high-dose testosterone).
Read more.
|
|
